Cytomegalovirus PP65 antigenemia monitoring as a guide for preemptive therapy: A cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients

Transplantation

Volumn 68, Issue 8, 1999, Pages 1125-1131

  Kusne, Shimon ^a   Grossi, Paolo ^a   Irish, William ^a   St George, Kirsten ^a   Rinaldo, Charles ^a   Rakela, Jorge ^a   Fung, John ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; OKT 3; PHOSPHOPROTEIN;

ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFECTION RISK; INTRAVENOUS DRUG ADMINISTRATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PATIENT MONITORING; PRIORITY JOURNAL; VIRUS RESISTANCE;

ADULT; COHORT STUDIES; COST-BENEFIT ANALYSIS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LIVER TRANSPLANTATION; MIDDLE AGED; MUROMONAB-CD3; PHOSPHOPROTEINS; PREVENTIVE MEDICINE; PROSPECTIVE STUDIES; RISK FACTORS; VIRAL MATRIX PROTEINS;

EID: 0033610462     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199910270-00011     Document Type: Article

References (62)

1. Kusne S, Dummer JS, Singh N, et al. Infections after liver transplantation, an analysis of 101 consecutive cases. Medicine 1988; 67: 132.
2. Kanj SS, Sharara AI, Clavien PA, Hamilton JD. Cytomegalovirus infection following liver transplantation: review of the literature. Clin Infect Dis 1996; 22: 537.
3. Singh N, Dummer JS, Kusne S, et al. Infections with cytomegalovirus and other herpes viruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis 1988; 158: 124.
4. Falagas ME, Arbo M, Ruthazer R, et al. Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients. Transplantation 1997; 63: 1595.
5. George MJ, Snydman DR, Werner BG. The independent role of Cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Am J Med 1997; 103: 106.
6. Patel R, Snydman DR, Rubin RH, et al. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996; 61: 1279.
7. Rubin RH. Preemptive therapy in immunocompromised hosts. N Engl J Med 1991; 324: 1057.
8. Snydman DR. Cytomegalovirus prophylaxis strategies in high-risk transplantation. Transpl Proc 1994; 26(suppl 1): 20.
9. Schmidt GM, Horak DA, Niland JC, et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 1991; 324: 1005.
10. Goodrich JM, Mori M, Cleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325: 1601.
11. Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowski T. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent Cytomegalovirus disease in liver transplant recipients. Ann Intern Med 1994; 120: 375.
12. Falagas ME, Snydman DR, Ruthazer R, Werner BG, Griffith J, and the Boston Center for Liver Transplantation CMVIG Study group. Surveillance cultures of blood, urine, and throat specimens are not valuable for predicting Cytomegalovirus disease in liver transplant recipients. Clin Infect Dis 1997; 24: 824.
13. Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent Cytomegalovirus disease in Cytomegalovirus antibody-positive renal transplant recipients. Ann Intern Med 1995; 123: 18.
14. van der Bij W, Schirm J, Torensma R, van Son J, Tegzess AM, The TH. Comparison between viremia and antigenemia for detection of cytomegalovirus in blood. J Clin Microbiol 1988; 26: 2531.
15. van den Berg AP, van der Bij W, van Son WJ, et al. Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation, a report of 130 consecutive patients. Transplantation 1989; 48: 991.
16. Boland GJ, deGast GC, Hene RJ, et al. Early detection of active cytomegalovirus (CMV) infection after heart and kidney transplantation by testing for immediate early antigenemia and influence of cellular immunity on the occurrence of CMV infection. J Clin Microbiol 1990; 28: 2069.
17. van den Berg AP, Klompmaker IJ, Haagsma EB, et al. Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation. JID 1991; 164: 265.
18. Erice A, Holm MA, Gill PC, et al. Cytomegalovirus (CMV) antigenemia assay is more sensitive than shell vial culture for rapid detection of CMV in polymorphonuclear blood leukocytes. J Clin Microbiol 1992; 30: 2822.
19. Halwachs G, Zach R, Pogglitech H, et al. A rapid immunocytochemical assay for CMV detection in peripheral blood of organ-transplanted patients in clinical practice. Transplantation 1993; 56: 338.
20. Schmidt CA, Oettle H, Peng R, et al. Comparison of polymerase chain reaction from plasma and buffy coat with antigen detection and occurrence of immunoglobulin M for the demonstration of cytomegalovirus infection after liver transplantation. Transplantation 1995; 59: 1133.
21. Niubo J, Perez JL, Martinez-Lacasa JT, et al. Association of quantitative cytomegalovirus antigenemia with symptomatic infection in solid organ transplant patients. Diagn Microbiol Infect Dis 1996; 24: 19.
22. Ehrnst A, Barkholt L, Brattstorm C, et al. Detection of CMV-matrix pp65 antigen in leukocytes by immunofluorescence as a marker of CMV disease. J Med Virol 1993; 39: 118.
23. Murray BM, Amsterdam D, Gray V, Myers J, Gerbasi J, Venuto R. Monitoring and diagnosis of Cytomegalovirus infection in renal transplantation. J Am Soc Nephrol 1997; 8: 1448.
24. Tanabe K, Tokumoto T, Ishikawa N, et al. Comparative study of Cytomegalovirus (CMV) antigenemia assay, polymerase chain reaction, serology, and shell vial assay in the early diagnosis and monitoring of CMV infection after renal transplantation. Transplantation 1997; 64: 1721.
25. Gaeta A, Nazzari C, Angelletti S, Lazzarini M, Mazzei E, Mancini C. Monitoring for Cytomegalovirus infection in organ transplant recipients: analysis of pp65 antigen, DNA and late mRNA in peripheral blood leukocytes. J Med Virol 1997; 53: 189.
26. Gerna G, Zipeto D, Parea M, et al. Monitoring of human Cytomegalovirus infections and ganciclovir treatment in heart transplant recipients by determination of viremia, antigenemia, and DNAemia. JID 1991; 164: 488.
27. Koskinen PK, Nieminen MS, Marttila SP, Hayry PJ, Lautenschlager IT. The correlation between symptomatic CMV infection and CMV antigenemia in heart allograft recipients. Transplantation 1993; 55: 547.
28. Iberer F, Tscheliessnigg K, Halwachs G, et al. Cytomegalovirus after heart transplantation: definitions for the guidance of antiviral therapy. Scand J Infect Dis 1995; suppl 99: 100.
29. Lo CY, Ho KN, Yuen KY, et al. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay. Clin Transplant 1997; 11: 286.
30. Grossi P, Minoli L, Percivalle E, Irish W, Vigano M, Gerna G. Clinical and virological monitoring of human cytomegalovirus infection in 294 heart transplant recipients. Transplantation 1995; 59: 847.
31. van den Berg, van Son WJ, Haagsma EB, et al. Prediction of recurrent cytomegalovirus disease after treatment with ganciclovir in solid organ transplant recipients. Transplantation 1993; 55: 847.
32. Starzl TE, Iwatsuki S, Van Thiel DH, et al. Evolution of liver transplantation. Hepatology 1982; 2: 614.
33. Todo S, Fung JJ, Starzl TE, et al. Single center experience with primary orthotopic liver transplantation under FK immunosuppression. Ann Surg 1994; 220: 297.
34. Revello MG, Percivalle E, Di Matteo A, Morini F, Gerna G. Nuclear expression of a lower matrix protein of human cytomegalovirus in peripheral blood leukocytes of immunocompromised viraemic patients. J Gen Virol 1992; 73: 437.
35. Ljungman P, Griffiths P. Definitions of cytomegalovirus infection and disease. In: Plotkins S, Michelson S, eds. Multidisciplinary approach to understanding cytomegalovirus disease. Amsterdam: Excerpta Medica International Congress Series, 1993:1032: 233.
36. Ljungman P, Plotkin SA. Worshop on CMV disease; definitions, clinical severity scores, and new syndromes. Scand J Infect Dis 1995; suppl 99: 87.
37. Gerna G, Revello MG, Percivalle E, Morini F. Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. J Clin Microbiol 1992; 30: 1232.
38. St. George K, Rinaldo CR. Comparison of commercially available antibody reagents for the cytomegalovirus pp65 antigenemia assay. Clin Diag Virol 1997; 7: 147.
39. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statis Assoc 1958; 53: 457.
40. Cox DR. Regression models and life tables (with discussion). J R Statis Soc Series B 1972; 34: 187.
41. SPSS Software for Windows. Chicago: SPSS Inc.
42. Pricing In: Drugs Topics Redbook, 1998 ed. Montvale, NJ: Medical Economics Company, Inc., 1998: 254.
43. Martin M, Manez R, Linden P, et al. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1994; 58: 779.
44. Turgeon N, Fishman JA, Basgoz N, et al. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent Cytomegalovirus disease in Cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy. Transplantation 1998; 66: 1780.
45. Merigan TC, Renlund DG, Keay S, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992; 326: 1182.
46. Snydman DR, Werner BG, Dougherty NN, et al. Cytomegalovirus Immune Globulin in liver transplantation, a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1993; 119: 894.
47. Winston DJ, Wirin D, Shaked A, Busutttil R. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver transplant recipients. Lancet 1995; 346: 69.
48. Gane E, Saliba F, Valdecasas GJC, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997; 350: 1729.
49. Grossi P, Kusne S, Rinaldo C, et al. Guidance of ganciclovir therapy with pp65 antigenemia in cytomegalovirus-free recipients of livers from seropositive donors. Transplantation 1996; 61: 1659.
50. Lautenschlager I, Hockerstedt K, Salmela K. Quantitative CMV-antigenemia test in the diagnosis of CMV infection in liver transplant recipients. Tranplant Proc 1994; 26: 1719.
51. Egan JJ, Barber L, Lomax J, et al. Detection of human cytomegalovirus antigenemia: a rapid diagnostic technique for predicting cytomegalovirus infection/pneumonitis in lung and heart transplant recipients. Thorax 1994; 50: 9.
52. Landry ML, Ferguson D. Comparison of quantitative Cytomegalovirus antigenemia assay with culture methods and correlation with clinical disease. J Clin Microbiol 1993; 31: 2851.
53. Meyer-Konig U, Serr A, von Laer D, et al. Human Cytomegalovirus Immediate Early and Late transcripts in peripheral blood leukocytes: diagnostic value in renal transplant recipients. JID 1995; 171: 705.
54. van der Bij W, Torensma R, van Son WJ, et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leukocytes. J Med Virol 1988; 25: 179.
55. Ghisetti V, Barbui A, Rocci MP, et al. Detection of human cytomegalovirus myocardial involvement by polymerase chain reaction during systemic infection and correlation with pp65 antigenemia and DNAemia in infected heart recipients. Transplantation 1996; 61: 1072.
56. Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. JID 1991; 163: 716.
57. Rosen HR, Benner KG, Flora KD, et al. Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation. Transplantation 1997; 63: 476.
58. Alain S, Honderlick P, Grenet D, et al. Failure of ganciclovir treatment associated with selection of a ganciclovir-resistant cytomegalovirus strain in a lung transplant recipient. Transplantation 1997; 63: 1533.
59. Baldanti F, Simoncini L, Sarasini A, et al. Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood. Transplantation 1998; 66: 324.
60. Gerna G, Zavattoni M, Percivalle E, Grossi P, Torsellini M, Revello MG. Rising levels of human Cytomegalovirus antigenemia during initial antiviral treatment of solid organ transplant recipients with primary HCMV infection. J Clin Microbiol 1998; 36: 1113.
61. The TH, van der Ploeg M, van den Berg AP, Vlieger Am, van der Giessen M, van Son WJ. Direct detection of cytomegalovirus in peripheral blood leukocytes-a review of the antigenemia assay and polymerase chain reaction. Transplantation 1992; 54: 193.
62. The TH, van den Berg AP, van Son WJ, et al. Monitoring for Cytomegalovirus after organ transplantation: a clinical perspective. Transpl Proc 1993; 25(suppl 4): 5.